Merck stock holds steady as Keytruda drives revenue growth and investors watch oncology momentum

Merck stock reflects a business increasingly dominated by oncology, with Keytruda and vaccines driving double-digit revenue growth and a solid market capitalization in the S&P 500 context.

Merck & Co., Inc. (ISIN US58933Y1055) is one of the largest US-based pharmaceutical groups and a constituent of the S&P 500 index, with Merck stock supported by a portfolio led by oncology blockbuster Keytruda and a broad vaccine business. In its most recently reported full year 2023, Merck generated total revenue of around $60.1 billion according to company information, highlighting the scale of its operations in prescription medicines, vaccines, and animal health. For investors, the balance between continued oncology growth and patent-expiry risk remains a central theme for Merck stock.

Revenue grows to about $60.1 billion

According to publicly available financial data summarizing Merck & Co.'s 2023 performance, total revenue in the full year reached roughly $60.1 billion, reflecting the company’s position among the top global pharmaceutical manufacturers. This revenue figure compares with approximately $52.0 billion in 2022, implying year-on-year growth of around $8.1 billion, or roughly 15.6%, driven primarily by cancer drug Keytruda and vaccines in human health. The increase underscores how Merck has been able to offset pressures in certain mature product categories with strong demand in oncology and immunology.

Within this overall revenue picture, Merck’s human health segment – which includes oncology, vaccines, hospital acute care, immunology, and other therapeutic areas – accounts for the majority of sales. Publicly available segment data indicate that human health contributed well over three quarters of total revenue in 2023, emphasizing the importance of prescription pharmaceuticals and vaccines relative to the smaller animal health business. Because many of these therapies address chronic and life-threatening conditions, they tend to generate recurring demand and can support relatively predictable cash flows over time, which is relevant for how Merck stock is valued in the wider healthcare sector.

Keytruda estimated above $25 billion sales

Keytruda, Merck’s flagship programmed death receptor-1 (PD-1) immune checkpoint inhibitor used in multiple oncology indications, is widely reported as the company’s single largest product by revenue. According to aggregated sell-side and industry estimates for 2023, Keytruda generated product sales estimated at more than $25 billion in that year, up from roughly the low-$20 billion range in 2022, implying double-digit growth in absolute dollar terms. This makes Keytruda one of the highest-revenue prescription medicines globally, and a central driver of Merck’s top line.

The growth trajectory of Keytruda has been supported by expanded indications across lung, melanoma, renal, and other cancers, as well as broader geographic uptake, but it also raises strategic questions around concentration risk as the drug approaches key patent-expiry windows later in the decade. For investors following Merck stock, the scale of Keytruda’s contribution means that future revenue diversification – including follow-on oncology assets and other immunology therapies – is a core topic in medium-term valuation discussions. Merck’s clinical pipeline features numerous combination therapies and next-generation immuno-oncology candidates designed to sustain oncology revenue as competitive and patent pressures emerge.

Non-Oncology segments and vaccines contribute billions

Beyond oncology, Merck’s vaccines franchise represents another substantial revenue pillar. Public data indicate that several vaccine brands – including human papillomavirus (HPV), pneumococcal, and pediatric vaccines – each generated more than $1 billion in annual 2023 sales, contributing multiple billions of dollars to total revenue. These vaccines address prevention of infectious diseases across age groups, and the recurring nature of vaccination schedules can provide a relatively stable revenue base even as individual product lifecycles evolve.

Merck also operates an animal health segment, supplying vaccines, pharmaceuticals, and technology solutions for livestock and companion animals. While smaller than the human health segment, animal health is reported to deliver several billion dollars of annual revenue, adding diversification beyond the human therapeutics portfolio. For Merck stock, this diversification can help smooth earnings volatility and mitigate single-product risk, especially as the oncology business dominates the company’s revenue mix.

Operating performance and margins watch

Operating metrics provide additional insight into Merck’s financial profile. In broad terms, Merck’s adjusted earnings per share (EPS) for 2023 are reported by market commentators to be in the mid-to-high single dollar range, reflecting solid profitability after accounting for research and development spending and other operating costs. Compared with 2022, this represents EPS growth consistent with revenue expansion, although reported GAAP EPS can be more volatile due to one-off items, impairments, or restructuring charges. The company’s operating margin – measured as operating income divided by total revenue – is typically cited in the low-to-mid 20 percent range in recent years, aligning with peers in large-cap pharmaceuticals.

Merck continues to invest heavily in research and development (R&D), with annual R&D expense commonly reported in the high single-digit billions of dollars. This spending level underscores the company’s commitment to maintaining a competitive pipeline in oncology, vaccines, and other therapeutic areas, and it is one reason why Merck’s margin profile must be interpreted alongside its innovation strategy. For Merck stock, the interplay between R&D intensity and margin stability is an important lens for long-term investors assessing the company’s ability to refresh its portfolio as legacy products approach loss of exclusivity.

Dividend and cash returns to shareholders

Merck & Co. has a longstanding track record of returning cash to shareholders through dividends. As of the latest published dividend data for 2023 and early 2024, the annual dividend per share is often cited around the mid-$2 range, which, combined with the prevailing share price, implies a dividend yield in the low-to-mid single digit percentage range. Historical patterns indicate Merck has frequently increased its dividend on a periodic basis over recent years, reflecting management’s confidence in the company’s cash-generation capacity.

In addition to dividends, Merck has periodically used share repurchases as another mechanism to return capital to shareholders, although the scale and timing of buybacks have varied depending on broader capital allocation priorities, including acquisitions and R&D investments. For investors analyzing Merck stock, the combination of a cash dividend and occasional buybacks contributes to the total shareholder return profile, which must be weighed against growth prospects and pipeline risk when comparing Merck with other large pharmaceutical peers.

Market capitalization near $300 billion

Merck stock trades on the New York Stock Exchange under the ticker MRK, and the company’s equity is one of the more heavily traded healthcare names in the US market. As of a recent market snapshot in mid-2026 from financial-data providers, Merck’s market capitalization is reported in the approximate range of $260 billion to $300 billion, placing it among the largest constituents of the global pharmaceutical sector by equity value. This scale reflects investor expectations for continued cash flows from Keytruda, vaccines, and the broader portfolio, as well as the embedded value of Merck’s pipeline and intellectual property.

Merck’s inclusion in major indices such as the S&P 500 and, in some healthcare-focused benchmarks, specialized pharma or biotech indices, also affects trading dynamics. Index membership can drive passive fund flows and influence demand for Merck stock independent of company-specific news. In periods where healthcare receives increased attention from asset allocators, Merck can benefit from sector-wide inflows, although it is also exposed to broader market risk, interest-rate sentiment, and regulatory developments affecting drug pricing in the US and other key markets.

Keytruda underpins Merck’s product mix

Keytruda’s role in Merck’s portfolio is central to understanding the company’s risk and opportunity profile. As a PD-1 inhibitor, Keytruda helps the immune system recognize and attack cancer cells, and it has secured approvals across multiple tumor types and lines of therapy. Its broad label drives sustained demand across lung cancer, melanoma, and other indications, and the drug’s performance largely explains why Merck’s oncology revenue has outpaced some more mature therapy areas. For Merck stock, this means that any material change in Keytruda’s competitive position, regulatory status, or clinical data can quickly influence sentiment.

At the same time, Merck is working to expand its oncology and immunology pipeline beyond Keytruda, including combination regimens with other agents and novel mechanisms aimed at solid tumors and hematologic malignancies. The objective is to ensure that, as Keytruda eventually faces biosimilar competition following loss of exclusivity, newer assets can sustain or even extend Merck’s presence in oncology. Investors often compare Merck’s pipeline depth and diversity with other large pharmaceutical groups when assessing long-term revenue replacement capacity, particularly in the context of Keytruda’s outsized share of total revenue.

Merck stock trading context and valuation

From a market perspective, Merck stock’s valuation metrics such as price-to-earnings (P/E) and enterprise value to EBITDA (EV/EBITDA) are frequently discussed in relation to peers like Pfizer, Bristol Myers Squibb, and Johnson & Johnson. While exact ratios fluctuate over time, Merck often trades at a premium to some traditional pharma names, reflecting its growth profile driven by oncology and vaccines. The combination of solid dividend yield, large-market capitalization, and key blockbuster exposure can make Merck a core holding in healthcare allocations, but it also means the stock is sensitive to any revision in medium-term Keytruda sales expectations.

Analysts following the company monitor not only reported quarterly figures but also guidance updates for revenue and EPS, as well as qualitative commentary on pricing and reimbursement trends in major markets. Regulatory initiatives aimed at limiting drug-price inflation in the US, such as negotiation frameworks for certain high-spend medicines, represent a structural consideration for Merck’s long-range planning. How Merck manages these evolving policy landscapes while sustaining innovation will continue to shape the narrative around Merck stock in global capital markets.

Representative product focus: Keytruda in lung cancer

Among Keytruda’s many indications, its use in non-small cell lung cancer (NSCLC) is one of the most commercially important. In this setting, Keytruda can be used as monotherapy or in combination with chemotherapy, depending on biomarkers such as PD-L1 expression. The clinical and commercial success of Keytruda in lung cancer has helped Merck capture a significant share of the global immuno-oncology market, reinforcing the drug’s position as a cornerstone therapy in frontline and subsequent treatment lines. For Merck, the continued expansion of lung cancer indications and international market penetration is a key factor sustaining the billions of dollars in annual Keytruda revenue.

Merck stock price and market snapshot

Merck stock is listed on the New York Stock Exchange, and shares trade in US dollars under the ticker MRK. As a large, widely followed pharmaceutical name, Merck typically records high daily trading volumes, reflecting interest from institutional, retail, and passive index investors. The company’s market capitalization in the broad range of approximately $260 billion to $300 billion, as referenced earlier, gives it significant weight in major indices and sector funds. For investors, the current share price level, in combination with dividend yield and earnings expectations, feeds into views about whether Merck offers defensive characteristics, growth exposure, or a mix of both within a diversified portfolio.

Merck & Co. key facts

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: NYSE: MRK
• Trading venue: NYSE
• Market capitalization: Approximately $260-300 billion range (as of mid-2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500